These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

703 related articles for article (PubMed ID: 29642874)

  • 1. Pilot evaluation of a second-generation electronic pill box for adherence to Bedaquiline and antiretroviral therapy in drug-resistant TB/HIV co-infected patients in KwaZulu-Natal, South Africa.
    Bionghi N; Daftary A; Maharaj B; Msibi Z; Amico KR; Friedland G; Orrell C; Padayatchi N; O'Donnell MR
    BMC Infect Dis; 2018 Apr; 18(1):171. PubMed ID: 29642874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence Measured Using Electronic Dose Monitoring is Associated with Emergent Antiretroviral Resistance and Poor Outcomes in People with Human Immunodeficiency Virus/AIDS and Multidrug-Resistant Tuberculosis.
    Bateman M; Wolf A; Chimukangara B; Brust JCM; Lessells R; Amico R; Boodhram R; Singh N; Orrell C; Friedland G; Naidoo K; Padayatchi N; O'Donnell MR
    Clin Infect Dis; 2022 Oct; 75(9):1489-1496. PubMed ID: 35352097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electronic Dose Monitoring Identifies a High-Risk Subpopulation in the Treatment of Drug-resistant Tuberculosis and Human Immunodeficiency Virus.
    Zelnick JR; Daftary A; Hwang C; Labar AS; Boodhram R; Maharaj B; Wolf AK; Mondal S; Amico KR; Orrell C; Seepamore B; Friedland G; Padayatchi N; O'Donnell MR
    Clin Infect Dis; 2021 Oct; 73(7):e1901-e1910. PubMed ID: 33053186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bedaquiline Adherence Measured by Electronic Dose Monitoring Predicts Clinical Outcomes in the Treatment of Patients With Multidrug-Resistant Tuberculosis and HIV/AIDS.
    O'Donnell MR; Padayatchi N; Wolf A; Zelnick J; Daftary A; Orrell C; Nimmo C; Baldwin M; Boodhram R; Maharaj B; Amico KR; Naidoo K; Friedland G
    J Acquir Immune Defic Syndr; 2022 Jul; 90(3):325-332. PubMed ID: 35195572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic needs and challenges of people with drug-resistant tuberculosis and HIV in South Africa: a qualitative study.
    Daftary A; Mondal S; Zelnick J; Friedland G; Seepamore B; Boodhram R; Amico KR; Padayatchi N; O'Donnell MR
    Lancet Glob Health; 2021 Apr; 9(4):e479-e488. PubMed ID: 33740409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
    Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preferential adherence to antiretroviral therapy over tuberculosis treatment: a qualitative study of drug-resistant TB/HIV co-infected patients in South Africa.
    Daftary A; Padayatchi N; O'Donnell M
    Glob Public Health; 2014; 9(9):1107-16. PubMed ID: 25035943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB.
    Pandie M; Wiesner L; McIlleron H; Hughes J; Siwendu S; Conradie F; Variava E; Maartens G
    J Antimicrob Chemother; 2016 Apr; 71(4):1037-40. PubMed ID: 26747099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection.
    O'Donnell MR; Padayatchi N; Daftary A; Orrell C; Dooley KE; Rivet Amico K; Friedland G
    Lancet HIV; 2019 Mar; 6(3):e201-e204. PubMed ID: 30846058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen.
    Ndjeka N; Schnippel K; Master I; Meintjes G; Maartens G; Romero R; Padanilam X; Enwerem M; Chotoo S; Singh N; Hughes J; Variava E; Ferreira H; Te Riele J; Ismail N; Mohr E; Bantubani N; Conradie F
    Eur Respir J; 2018 Dec; 52(6):. PubMed ID: 30361246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment outcomes in patients with drug-resistant TB-HIV co-infection treated with bedaquiline and linezolid.
    Padayatchi N; Bionghi N; Osman F; Naidu N; Ndjeka N; Master I; Brust JCM; Naidoo K; Ramjee A; O Donnell M
    Int J Tuberc Lung Dis; 2020 Oct; 24(10):1024-1031. PubMed ID: 33126934
    [No Abstract]   [Full Text] [Related]  

  • 12. Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa (ADAP-TIV): study protocol for an adaptive randomized controlled trial.
    Ross J; Perumal R; Wolf A; Zulu M; Guzman K; Seepamore B; Reis K; Nyilana H; Hlathi S; Narasimmulu R; Cheung YKK; Amico KR; Friedland G; Daftary A; Zelnick JR; Naidoo K; O'Donnell MR
    Trials; 2023 Dec; 24(1):776. PubMed ID: 38037105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study.
    Zhao Y; Fox T; Manning K; Stewart A; Tiffin N; Khomo N; Leslie J; Boulle A; Mudaly V; Kock Y; Meintjes G; Wasserman S
    Clin Infect Dis; 2019 Apr; 68(9):1522-1529. PubMed ID: 30165431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study.
    Schnippel K; Berhanu RH; Black A; Firnhaber C; Maitisa N; Evans D; Sinanovic E
    BMC Infect Dis; 2016 Oct; 16(1):593. PubMed ID: 27769174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment Adherence Among Persons Receiving Concurrent Multidrug-Resistant Tuberculosis and HIV Treatment in KwaZulu-Natal, South Africa.
    Stephens F; Gandhi NR; Brust JCM; Mlisana K; Moodley P; Allana S; Campbell A; Shah S
    J Acquir Immune Defic Syndr; 2019 Oct; 82(2):124-130. PubMed ID: 31513073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of cure among HIV co-infected multidrug-resistant TB patients at Sizwe Tropical Disease Hospital Johannesburg, South Africa.
    Umanah TA; Ncayiyana JR; Nyasulu PS
    Trans R Soc Trop Med Hyg; 2015 May; 109(5):340-8. PubMed ID: 25787727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of drug resistantTB in patients with HIV co-infection.
    Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Spanevello A; Migliori GB
    Expert Opin Pharmacother; 2015; 16(18):2737-50. PubMed ID: 26478945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
    Ferlazzo G; Mohr E; Laxmeshwar C; Hewison C; Hughes J; Jonckheere S; Khachatryan N; De Avezedo V; Egazaryan L; Shroufi A; Kalon S; Cox H; Furin J; Isaakidis P
    Lancet Infect Dis; 2018 May; 18(5):536-544. PubMed ID: 29452942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis.
    Ndjeka N; Conradie F; Schnippel K; Hughes J; Bantubani N; Ferreira H; Maartens G; Mametja D; Meintjes G; Padanilam X; Variava E; Pym A; Pillay Y
    Int J Tuberc Lung Dis; 2015 Aug; 19(8):979-85. PubMed ID: 26162365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with mortality among laboratory-diagnosed drug-resistant tuberculosis patients on treatment, KwaZulu-Natal Province, 2017-2019.
    Phafane MP; Ngozo J; Radebe Z; Lutge E; Ebonwu J
    Pan Afr Med J; 2024; 47():181. PubMed ID: 39092023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.